Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Office of the Director, 1600 Clifton Rd, NE, E-07, Atlanta, GA 30333, United States.
Drug Alcohol Depend. 2010 Jan 1;106(1):7-15. doi: 10.1016/j.drugalcdep.2009.07.015. Epub 2009 Aug 31.
Project RESPECT's brief risk reduction counseling (BRRC) reduced sexual risk and bacterial STIs among at-risk heterosexuals and has been packaged for use with this population. We assessed BRRC's efficacy with RESPECT participants who used drugs and examined BRRC's applicability to present-day users of heroin, cocaine, speedball, or crack.
We compared baseline demographic and economic variables, risk behaviors, and prevalence and correlates of bacterial STIs for ever-injectors ([EIs], N=335) and never-injectors ([NIs], N=3963). We assessed changes in risk behaviors and bacterial STIs for EIs and NIs at 12 months. We compared prevalence of HSV-2, hepatitis B core antigen virus (HBV), hepatitis C virus (HCV), and trichomonas among EIs with recently reported rates among drug users.
At baseline, 19% of EIs and 29% of NIs had bacterial STIs. Both groups had similar baseline STI correlates. At 12 months, 4% of EIs and 7% of NIs had bacterial STIs. Twelve-month cumulative incidence of bacterial STIs in BRRC was 21% lower among EIs and 18% lower among NIs compared to the informational condition. At 12 months, EIs reported fewer sexual risk behaviors than at baseline. Baseline positivity rates of trichomoniasis in EIs (female: 15%) and in male and female EIs of HSV-2 (39%, 68%), HBV (41%, 37%), and HCV (60%, 58%) were similar to rates in present-day drug users.
Efficacy of BRRC in reducing sexual risk and bacterial STIs in EIs, and similar profiles for EIs and present-day drug users suggest evaluating BRRC with present-day drug users.
项目尊重的简要风险减少咨询（BRRC）降低了高危异性恋者的性风险和细菌性性传播感染，并已包装供该人群使用。我们评估了 BRRC 在使用毒品的 RESPECT 参与者中的效果，并研究了 BRRC 对当今海洛因、可卡因、冰毒或快克使用者的适用性。
我们比较了既往注射者（[EIs]，N=335）和从未注射者（[NIs]，N=3963）的基线人口统计学和经济变量、风险行为以及细菌性性传播感染的患病率和相关因素。我们评估了 12 个月时 EIs 和 NIs 风险行为和细菌性性传播感染的变化。我们比较了 EIs 中单纯疱疹病毒 2（HSV-2）、乙型肝炎核心抗原病毒（HBV）、丙型肝炎病毒（HCV）和滴虫的患病率与近期药物使用者的报告率。
基线时，19%的 EIs 和 29%的 NIs 患有细菌性性传播感染。两组的基线性传播感染相关因素相似。12 个月时，4%的 EIs 和 7%的 NIs 患有细菌性性传播感染。与信息条件相比，BRRC 在 12 个月时 EIs 的细菌性性传播感染 12 个月累积发生率降低了 21%，NIs 降低了 18%。12 个月时，EIs 报告的性风险行为少于基线时。EIs 中滴虫病的基线阳性率（女性：15%）和男性和女性 EIs 中单纯疱疹病毒 2（39%，68%）、HBV（41%，37%）和 HCV（60%，58%）与当今药物使用者的比率相似。
BRRC 在降低 EIs 的性风险和细菌性性传播感染方面的疗效，以及 EIs 和当今药物使用者相似的特征表明，需要用当今药物使用者来评估 BRRC。
